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Myocardial infarction (MI) is the leading cause of death 
worldwide. MicroRNAs regulate the expression of their 
target genes, thus mediating a plethora of pathophysi-
ological functions. Recently, miRNA-24 emerged as an 
important but controversial miRNA involved in post-
MI responses. Here, we aimed at clarifying the effect of 
adenovirus-mediate intra-myocardial delivery of a decoy 
for miRNA-24 in a mouse MI model and to investigate 
the impact of miRNA-24 inhibition on angiogenesis and 
cardiovascular apoptosis. After MI induction, miRNA-24 
expression was lower in the peri-infarct tissue and its res-
ident cardiomyocytes and fibroblasts; while it increased 
in endothelial cells (ECs). Local adenovirus-mediated 
miRNA-24 decoy delivery increased angiogenesis and 
blood perfusion in the peri-infarct myocardium, reduced 
infarct size, induced fibroblast apopotosis and overall 
improved cardiac function. Notwithstanding these ben-
eficial effects, miRNA-24 decoy increased cardiomyo-
cytes apoptosis. In vitro, miRNA-24 inhibition enhanced 
ECs survival, proliferation and networking in capillary-
like tubes and induced cardiomyocyte and fibroblast 
apoptosis. Finally, we identified eNOS as a novel direct 
target of miR-24 in human cultured ECs and in vivo. Our 
findings suggest that miRNA-24 inhibition exerts distinct 
biological effects on ECs, cardiomyocytes and fibroblasts. 
The overall result of post-infarction local miRNA-24 inhi-
bition appears to be therapeutic.
Received 29 June 2012; accepted 12 April 2013; advance online  
publication 18 June 2013. doi:10.1038/mt.2013.89
INTRODUCTION
Ischemic heart disease is the leading cause of death worldwide.1 
Myocardial infarction (MI) occurs when a coronary artery is 
occluded, leading to insufficient oxygen supply to the myocardium 
and resulting in death of cardiomyocytes and non-myocyte cells, 
including fibroblasts and endothelial cells (ECs).2,3 This is accom-
panied by hypertrophic growth of cardiomyocytes and deposi-
tion of interstitial fibrosis in the non-infarcted tissues, which 
collectively and ultimately results in maladaptive left ventricular 
(LV) remodeling and heart failure.4 Conventional revasculariza-
tion procedures aimed at reopening the obstructed artery, such 
as thrombolysis, angioplasty, and bypass surgery have improved 
the post-MI survival rate. However, these techniques cannot be 
applied to many patients and are prone to failure. Regenerative 
medicine represents a new hope for overcoming the limitation 
of conventional treatments for ischemic heart disease. Although 
traditional revascularization approaches target large vessels, ther-
apeutic angiogenesis research seeks to improve the microcircu-
lation by stimulating new capillary and collateral arterial vessel 
formation.5 Angiogenesis gene therapy based on the delivery of 
single growth factors has shown promises in small animal models 
of acute MI, but has so far failed to conclusively demonstrate ther-
apeutic efficacy in double blinded, randomized clinical trials on 
large patient populations.6,7 This may be accounted by a series of 
factors, including the chosen growth factors, delivery strategy, and 
patient selections and should be addressed at translational level.
Recently, microRNAs (miRs) have come into focus of car-
diovascular and angiogenesis research.8 In their mature form, 
miRs are small (21 to 25 nucleotides) endogenous non-coding 
RNAs that modulate gene expression, mainly by binding to the 3′ 
untranslated region (3′-UTR) of their targeted messenger RNAs 
(mRNAs), thus resulting in mRNA degradation or translational 
repression.9 So far, in excess of 1,000 miRs have been described 
in mammals and it is believed that >60% of protein coding genes 
are under the control of miRs.10 Each miR regulates the expres-
sion of several target genes, with the possibility to modulate 
seve ral molecular pathways. Hence, it is possible that some miRs 
could contribute into post-ischemic vascular repair and cardiac 
regeneration at multiple levels. In line with this hypothesis, an 
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increasing number of studies show that miR expression is altered 
in the infarcted heart and that miRs are involved in the regula-
tion of post-MI cardiac angiogenesis,11,12 apoptosis,13–15 and fibro-
sis.16–19 Of particular interest is miR-24, which has been recently 
implicated in post-MI responses. However, two leading groups 
have reported contrasting results on the expressional regulation 
and actions of this miR in the mouse acute MI setting.12,14 Fiedler 
et al. found that cardiac ECs express miR-24 under basal condi-
tions and that endothelial miR-24 levels are increased after MI. 
They additionally showed that silencing of miR-24 by systemic 
delivery of a modified antisense oligonucleotide (antagomir) 
improves post-MI reparative angiogenesis and preserves cardiac 
function in mice.12 By contrast, Qian et al. could not detect miR-
24 in cardiac ECs and observed a MI-induced downregulation of 
miR-24 in the peri-infarct area that correlates with increased car-
diomyocyte apoptosis.14 Most important, in striking contrast with 
Fielder et al., Qian et al. found that one intra-myocardial injec-
tion of precursor miR-24 (pre-miR-24) was enough to improve 
post-MI cardiac function in mice. The two studies attributed the 
cardiac effects of miR-24 to different target genes, namely the 
pro-angiogenic PAK4 (p21 protein-Cdc42/Rac-activated kinase 
4) and GATA2 (globin transcription factor binding protein 2) in 
Fiedler et al. and the pro-apoptotic BIM (BCL2-like 11 apoptosis 
facilitator) in Qian et al.12,14 In support to the latter study, a report 
showed that ex-vivo miR-24 enrichment improves the therapeutic 
potential of cardiac progenitor cells upon their transplantation in 
a rodent MI model.20 More recently, lentivirus-mediated cardiac 
miR-24 overexpression has been shown to attenuate cardiac fibro-
sis and improve cardiac function after MI in mice.21
Given the aforementioned controversies present in the lit-
erature and the importance of defining miR-24 functions before 
moving to translational studies, we aimed at clarifying the cel-
lular expression of miR-24 in the post-MI setting, the miR-24 
role in angiogenesis and cardiac apoptosis, and the effect of local 
miR-24 inhibition by using an adenoviral vector carrying a decoy 
sequence for miR-24 (Ad.decoymiR-24; control: Ad.Null) in the 
same mouse MI model used in refs. 12,14,21.
RESULTS
Expression of cardiac miR-24 in the post-MI setting
To evaluate the expression of miR-24 after MI, different cardiac 
regions were isolated at 1 and 3 days after surgery to induce MI or 
sham-operation. Whereas miR-24 levels were similar in the right 
ventricle (RV) and septum (S) of infarcted and sham-operated 
mice, miR-24 expression was downregulated in the peri-infarct 
area as compared with either the LV of sham-operated mice or 
the LV remote zone isolated from infarcted hearts (Figure 1a and 
Supplementary Figure S1a). The mRNA relative expression of 
the miR-24 target genes BIM and GATA2 was similar in all cardiac 
regions (Supplementary Figure S1b,c) while PAK4 was upregu-
lated by MI at 1 and 3 days after MI (Supplementary Figure S1d). 
Next, to better understand miR-24 expressional changes at the cel-
lular level, we extracted ECs, cardiomyocytes and fibroblasts from 
infarcted and sham-operated hearts. Myocardial CD146+ ECs were 
magnetic sorted from the peri-infarct and remote areas of the LV 
at 1 and 3 days after MI. ECs prepared from the LV of sham-oper-
ated mice were used as reference. As shown in Supplementary 
Figure S2a–c, 84.5 ± 3.9% of CD146+ cells magnetic sorted from 
Figure 1 Myocardial infarct-induced microRNA-24 expressional changes in the mouse myocardium and its resident cells. At 1 and 3 days 
after surgery to myocardial infarct (MI) or sham-operation in mice, microRNA-24 (miR-24) relative expression was evaluated in (a) different cardiac 
regions and in (b) CD146+ endothelial cells (ECs), (c) cardiomyocytes and (d) fibroblasts isolated from sham-operated or infarcted (peri-infract area 
and remote area) left ventricles. Data are expressed as mean ± SEM. N = 3–4/group for cardiac regions analyses. For cellular expressional analyses, 
each preparation was obtained pooling cells from two hearts (N = 3–5 pools/group). Small nuclear RNA U6 (snU6) was used for normalization and 
data are reported to the control group by the 2-∆∆Ct formula. *P < 0.05 versus sham-operated LV; †P < 0.05 versus LV remote area; §P < 0.05 versus 
cells of sham-operated LV; ‡P < 0.05 versus cells of LV remote area. LV, left ventricle; Rem, LV remote area; RV, right ventricle; Peri, LV peri-infarct area; 
S, septum.
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the mouse LV coexpressed the CD31 endothelial marker, thus 
confirming that our protocol was highly enriching for ECs. As 
shown in Figure 1b, in comparison with ECs taken from the sham-
operated heart, miR-24 expression was significantly increased in 
CD146+ ECs isolated from the peri-infarct zone but not from the 
remote area, suggesting that myocardial ischemia increases miR-
24 expression in ECs. In addition, miR-24 expression was evalu-
ated in cardiomyocytes and fibroblasts isolated from the infarcted 
or sham-operated LV. Supplementary Figure S1d,e, respectively, 
present the characterization of the cardiomyocytes (stained with 
an antibody for α-sarcomeric actin) and fibroblasts (stained with 
an antibody for vimentin) prepared from the mouse heart. In 
agreement with Qian et al.,14 in comparison with cardiomyocytes 
from sham-operated heart, miR-24 was downregulated in cardio-
myocytes extracted from the LV peri-infarct, but not the remote 
zone (Figure 1c). Finally, miR-24 expression was also reduced in 
fibroblasts isolated from the LV peri-infarct in comparisons with 
cells from either sham-LV or LV remote area (Figure 1d).
miR-24 in angiogenesis and EC apoptosis
Fiedler et al. reported that blocking miR-24 increases the angio-
genic potential of human umbilical vein ECs (HUVECs).12 We 
have confirmed the data. Supplementary Figure S3a show 
the expected changes in miR-24 expression after transfection 
of HUVECs with synthetic miR-24 precursor (pre-miR-24), 
an anti-miR-24 inhibitor (anti-miR-24) or a negative con-
trol (scramble). Supplementary Figure S4a–d show Matrigel 
assays performed with HUVECs after miR-24 inhibition. Next, 
we extended the investigation to human microvascular ECs 
(HMVECs) because they better reflect the EC populations con-
tributing into neoangiogenesis. Efficiency of HMVECs trans-
fection by either pre-miR-24 or anti-miR-24 was confirmed 
by Taqman RT-PCR (Supplementary Figure S3b). As shown 
in Figure 2a–c, in comparison with the negative control, pre-
miR-24 impaired the formation of cellular networks from 
HMVECs seeded on Matrigel, whereas anti-miR-24 induced the 
opposite effect. In addition, pre-miR-24 inhibited HMVEC pro-
liferation (Figure 2d) and increased HMVECs apoptosis (Figure 
2e). Fiedler et al. reported PAK4 and GATA2 as miR-24 direct 
target genes and regulators of the pro-angiogenic effects medi-
ated by miR-24 inhibition in HUVECs.12 As shown in Figure 
2f, we confirm the data in HMVECs, where pre-miR-24 reduces 
and anti-miR-24 increase the expression of both target genes. In 
addition, the pro-apoptotic BIM was increased by anti-miR-24 
in HMVECs. This is at contrast with the knowledge that BIM is 
a direct target gene of miR-24.14 Nonetheless, this is in line with 
the observed anti-apoptotic action exerted by miR-24 inhibition 
in ECs (Figure 2e).
As additional tool to inhibit miR-24, we have prepared a 
decoy for miR-24 using a similar method already published 
in ref. 22 for miR-503 inhibition. Supplementary Figure S4e 
shows the miR-24 decoy structure. The decoy was then inserted 
in an adenoviral vector (Ad.decoymiR-24). The capacity of the 
decoy to bind to miR-24, thus reducing EFGP signal was vali-
dated in vitro (Supplementary Figure S4f). In HMVECs Ad.
decoymiR-24 upregulated GATA2 and PAK4 mRNA expres-
sion and increases angiogenesis in comparison with Ad.Null 
(Figure  2g,h Supplementary Figure S4c,d, respectively). The 
effect of in vivo miR-24 inhibition on GATA2, PAK4 and BIM 
was additionally evaluated in CD146+ ECs isolated from the 
LV at 3 and 14 days after MI and Ad.decoymiR-24 or Ad.Null. 
As shown in Figure 2j, GATA2 expression was unchanged. 
However, Ad.decoymiR-24 increased PAK4 mRNA relative 
expression in cardiac ECs at 3 days after MI (Figure 2k), thus 
validating PAK4 as miR-24 target in our in vivo model. At the 
same time point, Ad.decoymiR-24 decreased miR-24 levels in 
cardiac ECs (Supplementary Figure S5a). At 14 days, this effect 
was lost (data not shown), thus suggesting that the inhibitory 
effect of Ad.decoymiR-24 are no longer effective on ECs at this 
time point. Of note, BIM expression in CD146+ ECs was not 
affected by miR-24 inhibition (data not shown).
Identification of eNOS as a miR-24 direct target gene
To investigate whether additional factors besides PAK4 and 
GATA2 could be involved in the pro-angiogenic effects triggered 
by miR-24 inhibition, we searched for predicted target of miR-24 
which may favor EC homeostasis and angiogenesis. Both mouse 
vascular endothelial growth factor (vegf) and human VEGF were 
predicted as direct targets of miR-24 by six (DIANAmT, miRanda, 
miRWalk, PICTAR5, RNA22, and TargetScan) out of the nine 
searched bioinformatic platforms. Human VEGF was addition-
ally indicated by miRwalk as a validated target gene of miR-24.23 
Moreover, human endothelial nitric oxide synthases (eNOS, 
NOS3) was predicted as target gene of miR-24 by TargetScan 
(Figure 3a). A luciferase reporter gene assay confirmed miR-24 
binding to wild type eNOS 3′-UTR, while the miR-24 binding was 
impaired by mutation in the eNOS-3′-UTR (Figure 3b), thus vali-
dating eNOS as direct target gene of miR-24. Moreover, by align-
ing human miR-24 sequence to mouse eNOS 3′-UTR sequence 
using RNAhybrid software, we additionally verified that the bind-
ing site for miR-24 on eNOS 3′-UTR is conserved in mouse and 
human (Supplementary Figure S6).
Next, we performed eNOS and VEGF-A western blots analy-
ses on HMVECs pretreated with pre-miR-24, anti-miR-24 or 
scramble negative control. As shown in Figure 3c,d, in compari-
son with negative control, pre-miR-24 reduced eNOS mRNA and 
protein expression, whereas anti-miR-24 showed the opposite 
effects. By contrast, VEGF-A protein level were not changed by 
either pre-miR-24 or anti-miR-24 (data not shown). In addition, 
eNOS relative expression was upregulated by Ad.decoymiR-24 in 
HMVECs (Figure 2e). Next, the effect of in vivo miR-24 inhibi-
tion were evaluated in CD146+ ECs isolated at 3 days after sur-
gery from the peri-infarct myocardium treated with either Ad.
decoymiR-24 or Ad.Null or the sham-operated LV treated with Ad.
Null. CD146+ ECs eNOS mRNA relative expression was similar in 
all groups (Figure 3f). However, eNOS activity was increased in 
CD146+ ECs isolated at 3 days after MI and Ad.decoymiR-24 (P < 
0.05 versus MI/Ad.Null, Figure 3g). In addition, western blot anal-
yses on the peri-infarct tissue at 3 days after MI showed that eNOS 
expression was increased after Ad.decoymiR-24 (Figure 3h), thus 
further suggesting eNOS to be targeted by miR-24 in vitro and in 
vivo. Similarly to what observed in HMVECs, VEGF-A protein 
level in the peri-infarcted heart was unchanged by miR-24 inhibi-
tion (data not shown).
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miR-24 in cardiomyocyte and fibroblast apoptosis
To confirm the pro-apoptotic effect of miR-24 inhibition described 
by Qian et al. in cardiomyocytes,14 the murine cardiomyocyte cell 
line HL1 was transfected with Ad.decoymiR-24 or control Ad.Null 
and subjected to two apoptosis assays. Both Caspase-GLO assay 
and Cell Death Detection ELISA showed increased apoptosis in 
HL1 cells after Ad.decoymiR-24 (Figure 4a,b, respectively), thus 
confirming that miR-24 exerts pro-survival actions in cardiomyo-
cytes. In addition, in line with Qian et al.,14 BIM mRNA relative 
expression in HL1 increased by twofold following Ad.decoymiR-24 
Figure 2 miR-24 modulates HMVEC networking on Matrigel, proliferation and apoptosis and regulates the expression of target genes. 
(a) Photomicrograph show the endothelial network formation on Matrigel (scale bar 20 µm) of HMVECs transfected with pre-miR-24, anti-miR-24, 
or negative control (scramble). Bar graphs show (b) total length of tube-like structures and (c) percentage of area covered by connected tubular 
structures. Bar graphs show (d) BrdU incorporation and (e) Caspase activity assay of transfected HMVECs. Bar graphs show the expression of (f) the 
miR-24 target genes GATA2, PAK4 and BIM on HMVECs after transfection with pre-miR-24, anti-miR-24 or scramble and of (g) GATA2 and (h) PAK4 
after infection with Ad.decoymiR-24 or Ad.Null (control). (j) GATA2 and (k) PAK4 relative expression was additionally evaluated in CD146+ ECs isolated 
from the total LV (for sham-operated mice) or the LV peri-infarct myocardium at 3 days after surgery and gene transfer. Data are expressed as mean 
± SEM. Experiments in HMVECs were performed in triplicate and repeated 3 times. Each preparation of CD146+ cells was obtained pooling cells 
from two hearts (N = 3–4 pools/group). Three days in advance, the hearts received surgery and were infected with either Ad.decoymiR-24 or Ad.Null. 
Expressional analyses employed snU6 (for miRNA analyses) and 18S ribosomal RNA (RNA 18S) (for mRNA analyses) for normalization and data are 
reported to the control group by the 2-∆∆Ct formula. RLU: Relative Luminescent Units. *P < 0.05 and **P < 0.01 versus Scramble; †P < 0.05 and ††P 
< 0.01 versus pre-miR-24; §§P < 0.01 versus Ad.Null in HMVECs; ‡P < 0.05 versus ECs from Sham/Ad.Null hearts; #P < 0.05 versus ECs from MI/Ad.Null 
hearts.
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(Figure 4c). In vitro experiments on adult mouse cardiomyocytes 
confirmed that Ad.decoymiR-24 induces cardiomyocyte apoptosis 
and upregulates BIM mRNA level (Figure 4d,e, respectively). These 
data confirm with a different approach the anti-apoptotic effect of 
miR-24 in cardiomyocytes14 and the possible involvement of BIM 
inhibition in this response. Ad.decoymiR-24 additionally upregu-
lated eNOS RNA level in cultured cardiomyocytes (Figure  4f). 
However, this was not sufficient to promote cell survival, probably 
because of the prevalent action of BIM or other possible pro-apop-
totic miR-24 target genes in the cardiomyocyte. Next, we examined 
BIM changes induced by MI and in vivo Ad.decoymiR-24 in cardio-
myocytes. At 14 days after MI, as compared with MI/Ad.Null, Ad.
decoymiR-24 increased BIM relative expression in cardiomyocytes 
(Figure 4g). At the same time point, Ad.decoymiR-24 decreased 
miR-24 levels in cardiomyocytes (Supplementary Figure S5b), 
thus suggesting that Ad.decoymiR-24-mediated miR-24 inhibition 
Figure 3 eNOS is a direct target of miR-24. (a) Prediction of human eNOS as miR-24 target gene by TargetScan. (b) Luciferase assay for eNOS 
3′-UTR. HEK293 cells were cotransfected with pre-miR-24 (miR-24) or scramble oligonucleotides (control) and 3′-UTR-eNOS plasmid, express-
ing wild type or mutated (mut) sequences at the putative miR-24 target site. Luciferase activity was measure at 48 hours from transfection. Bar 
graphs show (c) eNOS mRNA relative expression and (d) representative western blots bands and relative protein quantification for eNOS on 
HMVECs transfected with pre-miR-24, anti-miR-24, or scramble. Tubulin was used as loading control. (d) Bar graphs show eNOS mRNA rela-
tive expression on HMVECs infected with Ad.decoymiR-24 or Ad.Null. Experiments on cultured ECs were performed in triplicate and repeated 
two times. (f) eNOS mRNA relative expression and (g) eNOS activity assay on CD146+ ECs isolated at 3 days after surgery and gene transfer as 
described in legend to Figure 2. N = 3–4 pools/group. (h) Representative western blot bands and relative quantification of eNOS protein expres-
sion in mouse myocardium at 3 days after MI and gene transfer. N = 4–5 mice/group. eNOS mRNA analyses employed RNA 18S for normalization 
and data are reported to the control group by the 2-∆∆Ct formula. All data are expressed as mean ± SEM. *P < 0.05 versus premiR-24; †P < 0.05 
versus scramble; §P < 0.05 and §§P < 0.01 versus Scramble; ‡‡P < 0.01 versus pre-miR-24; MI/Ad.Null; ##P < 0.01 versus Ad.Null; ǂǂP < 0.01 and ǂP < 
0.05 versus Sham/Ad.Null; ¥P < 0.05 versus MI/Ad.Null.
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Figure 4 miR-24 inhibition induces apoptosis and increases BIM expression in cardiac myocytes. Apoptosis of cultured murine HL1 cardiomyocytes 
treated with either Ad.Null or Ad.decoymir-24 was measured by (a) Caspase-GLO activity assay and (b) Cell Death Detection ELISA. (c) BIM relative expres-
sion in HL1 cells infected with Ad.Null or Ad.decoymiR-24. (d) Caspase-GLO activity assay and mRNA relative expression of (e) BIM and (f) eNOS on adult 
cardiomyocytes after in vitro infection with Ad.Null or Ad.decoymiR-24. Experiments were performed in duplicate and repeated 3 times. (g) BIM mRNA 
relative expression on cardiomyocytes isolated at 3 and 14 days after surgery and gene transfer (N = 3–5 pools/group). Data are expressed as mean ± SEM. 
BIM and eNOS mRNA analyses employed RNA 18S for normalization and data are reported to the control group by the 2-∆∆Ct formula. RLU: Relative 
Luminescent Units; OD: optical density. *P < 0.05 versus Ad.Null; ††P < 0.01 and †P < 0.05 versus Sham/Ad.Null; §P < 0.05 versus MI/Ad.Null.
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Figure 5 miR-24 inhibition induces apoptosis and increases BIM expression in cardiac fibroblasts. Bar graph shows (a) apoptosis (evaluated by 
Caspase-GLO activity assay) and (b) miR-24 target genes on cultured cardiac fibroblasts after transfection with anti-miR-24 or scramble (control). (c) 
RT-PCR for BIM assessed on cardiac fibroblasts isolated from mouse LV at 3 days after MI and gene transfer. Data are expressed as mean ± SEM. N = 2 
samples/group for transfection experiments. Fibroblasts isolated form infected LV were combined in pools of 2 samples (N = 3–4 pools/group). mRNA 
analyses employed RNA 18S for normalization and data are reported to the control group by the 2-∆∆Ct formula. *P < 0.05 versus Scramble; †P < 0.05 
versus Sham/Ad.Null; §P < 0.05 versus MI/Ad.Null.
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is still effective on cardiomyocytes at this time point. Of note, in line 
with Fiedler et al., GATA2 and PAK4 were not detected in cardio-
myocytes (data not shown).
The effect of miR-24 inhibition on cardiac fibroblasts has been 
also taken into account. Fibroblasts were transfected with anti-
miR-24 or scramble control. Efficacy of transfection in regulat-
ing miR-24 expression was validated by PCR (Supplementary 
Figure S3c). Next, fibroblasts were prompted in Caspase activity 
assay, which showed their increased apoptosis following miR-24 
inhibition (Figure 5a). Moreover, anti-miR-24 led to a significant 
upregulation of BIM, but did not affect the other studied target 
genes (Figure 5b). Similar results were obtained by Ad.decoymiR-
24-induced miR-24 inhibition (data not shown). Finally, target gene 
analyses in cardiac fibroblasts isolated from the LV at 3 days after 
MI and adenovirus infection showed that Ad.decoymiR-24 induced 
upregulation of BIM in comparison with Ad.Null (Figure  5c), 
whereas no significant effect on GATA2 and eNOS were observed 
(data not shown) and PAK4 was not detected.
Effect of miR-24 inhibition on microvascular density 
and blood flow in the infarcted myocardium
We next sought to evaluate the effect of local miR-24 inhibition 
by Ad.decoymiR-24 in the mouse MI model. At 14 days after MI 
induction, the numbers of capillaries (Figure 6a,d) and of small 
(diameter <50 µm) arterioles (Figure 6b,d) in the peri-infarct 
area were significantly increased by Ad.decoymiR-24 in com-
parison with Ad.Null. Importantly, the increase in microvascular 
density was associated with improved myocardial blood perfusion 
(revealed by using fluorescent microspheres) in mice given Ad.
decoymiR-24 (Figure 6c).
Effects of miR-24 inhibition on cardiovascular 
apoptosis in the infarcted myocardium
Apoptosis of ECs, cardiomyocytes, and fibroblasts is report-
edly increased after MI.24–26 Here, we evaluated whether Ad.
decoymiR-24 impacts on apoptosis in the peri-infarct area at 14 
days after surgery. By in situ TUNEL assay, we found that Ad.
decoymiR-24 increased by 2.2-folds the percentage of apoptotic 
cardiomyocyte nuclei (11.6 ± 0.7 versus 5.3 ± 1.5 in mice treated 
with Ad.Null; P < 0.05) (Figure 7a,d). By contrast, no effect of 
Ad.decoymiR-24 on EC survival was observed at this time point 
(Figure 7b,e). In addition, Ad.decoymiR-24 increased the percent-
age of apoptotic fibroblasts in the peri-infarct area (Figure 7c,f).
Effects of miR-24 inhibition on cardiac function after 
MI
The infarcted heart undergoes functional and dimensional 
changes.27 Occlusion of a coronary artery leads to enlargement 
of the LV chamber volume and reduction of the myocardial 
contractile performance.25,27 To date, positive effects on cardiac 
function have been described after either inhibition12 or over 
expression14 of the miR-24 in the setting of acute MI in mice. In 
the present study, cardiac function was measured by echocardiog-
raphy and Millar tip-catheter at 14 days after MI. As expected, 
Figure 6 miR-24 inhibition increases vessels density and improves blood perfusion in the infarcted myocardium. Bar graphs show the (a) capil-
lary and (b) small arteriole (<50 µm in lumen) densities in the peri-infarct region and the (c) LV blood flow at 14 days after surgery. (d) Representative 
microphotographs showing the peri-infarct area of Ad.Null and Ad.decoymiR-24 injected hearts after staining with the endothelial marker Isolectin-B4 
(in red) and with a fluorescent antibody for the mural cell marker α-SMA (in green and pointed by arrows, for arterioles). Scale bars: 20 µm. Data 
are expressed as mean ± SEM. (N = 6–7 mice/group for histological analyses, 8 mice/group for evaluation of LV perfusion). *P < 0.05 and **P < 0.01 
versus Sham/Ad.Null; †P < 0.05 versus MI/Ad.Null.
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in comparison with sham-operated mice, worsening of LV func-
tion was observed in MI mice for all analyzed parameters (Figure 
8a–f). However, Ad.decoymiR-24 improved ejection fraction (EF) 
and fractional shortening (FS) (Figure 8a,b, respectively) in com-
parison with Ad.Null. In addition, dP/dtmax (an index of ventricu-
lar contractile performance) was improved by miR-24 inhibition 
(Figure 8c), whereas no significant changes were observed for dP/
dtmin (Figure 8d). Moreover, despite ventricular dilatation being 
evident in the MI mice, Ad.decoymiR-24 led to a small but sig-
nificant reduction of both the LV internal diameter (Figure 8e) 
and LV chamber volume (Figure 8f) compared with Ad.Null, thus 
suggesting that miR-24 inhibition positively impacts on post-MI 
LV remodeling and function. This set of data is in agreement with 
what reported by Fiedler et al. using antagomir for miR-24.12 In 
addition, TTC staining performed at 14 days after MI revealed 
that Ad.decoymiR-24 reduced infarct size (Figure 8g), thus further 
Figure 7 miR-24 inhibition induces apoptosis of cardiomyocytes and fibroblasts but not ECs in the peri-infarct myocardium. Quantification 
of TUNEL positive (a) apoptotic cardiomyocyte nuclei, (b) ECs, and (c) fibroblasts following TUNEL assay in paraffin sections from peri-infarct region 
at 14 days after MI. (d) Representative pictures after staining for TUNEL (red) and α-sarcomeric actin (green) showing apoptotic cardiomyocytes 
(in purple and pointed by white arrows). (e) Representative pictures of apoptotic ECs (in purple and pointed by red arrows) evaluated after staining 
for TUNEL (in red) and isolectin-B4 (in green). Nuclei are depicted in blue (DAPI). (f ) Representative pictures of apoptotic fibroblasts (in purple and 
pointed by red arrows) evaluated after staining for TUNEL (in red) and vimentin (in green). Asterisks indicate the infarct area. Scale bars: 20 µm. Data 
are expressed as mean ± SEM. (N = 5 mice/group). **P < 0.01 and *P < 0.05 versus MI/Ad.Null.
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supporting the cardiac functional improvement observed after MI 
and miR-24 inhibition.
DISCUSSION
Recent studies have implicated miRs in a substantial variety of 
biological processes and diseases. Some miRs and several hun-
dred miR-regulated target genes have been shown to participate in 
cardiovascular development28–31 as well as cardiovascular diseases, 
including MI.12,14
To better understand the role of miRs in physiology, dis-
eases and as therapeutics, molecular tools allowing for miR 
forced expression or inhibition are essential. Therapeutic 
delivery of “good” miRs by using either adenoviral (Ad)32 or 
adeno- associated viral (AAV) vectors33 proved to be adequate at 
modulating miR expression and showed therapeutic promises in 
animal MI models. On the other side, inhibition of pathogenetic 
miRs by modified antisense oligonucleotides (antagomirs),12,18 
miR sponges34 or miRs decoys22,32 has also showed therapeutic 
efficacy. Antagomirs are still the predominant tools employed for 
systemic miR inhibition.35 Notwithstanding, we believe that the 
use or improved viral vectors for either induction or repression 
of miRs can be useful, especially to confer a local, longer-lasting 
Figure 8 Local Ad.decoy-mediated inhibition of miR-24 improves cardiac function after MI. Bar graphs showing (a) LV ejection fraction, (b) 
fractional shortening, (c) dP/dtmax, (d) dP/dtmin, (e) end-systolic LV internal diameter (LVID), and (f) end-systolic LV chamber volume evaluated at 
14 days after MI and gene transfer. a, b, e, and f were measured by echocardiography; c and d were assessed by Millar tip-catheter. (g) Bar graphs 
and representative pictures show the percent of infarct area evaluated in MI hearts at 14 days after surgery after TTC staining. Data are expressed as 
mean ± SEM. (N = 12 mice/group for functional analyses and five mice/groups for infarct size). *P < 0.05 and **P < 0.01 versus Sham/Ad.Null; †P < 
0.05 versus MI/Ad.Null.
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and robust expression of the therapeutic construct after a single 
administration dose.
Recently, miR-24 has emerged as an important but controver-
sial miR involved in post-MI recovery.12,14,21 Hence, we considered 
worth to further investigating on the cardiovascular actions and 
possible therapeutic potential of miR-24 expression modulation. 
miR-24 level has been previously shown to be increased in ECs of 
the mouse heart peri-infarct zone at early time points after MI.12 
However, Qian et al. disputed the presence of miR-24 expression 
in mouse myocardial ECs.14 This is quite surprising, as miR-24 
has been described to be highly expressed in ECs isolated from 
several tissues.36 In line with these observations, we found that 
miR-24 is expressed in HUVECs, HVMECs and mouse myocar-
dial CD146+ ECs and it is upregulated in CD146+ cells of the peri-
infarct myocardium. This is in agreement with Fiedler et al.12 On 
the other hand, similarly to what has been shown by Qian et al.14 
and Wang et al.,21 we found that miR-24 is downregulated in the 
peri-infarct tissue as compared with both sham-operated LV and 
the LV remote zone isolated from infarcted hearts. Moreover, our 
data show that MI reduces miR-24 levels in both cardiomyocytes 
and fibroblasts.
To understand the impact of miR-24 on the angiogenic pro-
cess, in vitro studies on ECs were performed. The pro-angiogenic 
role of miR-24 has been already elucidated by Fiedler et al. dur-
ing zebrafish development and using HUVECs.12 Here, to better 
represent the EC contributing to adult neoangiogenesis we addi-
tionally employed adult HMVECs. Similarly to what previously 
observed in HUVECs,12 synthetic miR-24 precursor (pre-miR-24) 
impaired HMVEC networks formation on Matrigel, whereas 
miR-24 inhibition by anti-miR-24 improved HMVEC networking 
capacity.
Many pro- and anti-angiogenic factors are involved in the 
angiogenesis response to physiological or pathological stimuli. 
Among them, nitric oxide released by eNOS is recognized as an 
essential factor which induces vasodilation and modulates post-
ischemic angiogenesis.37 In the present study, we have newly 
identified eNOS as a target of miR-24 in cultured ECs as well as 
in the infarcted heart. In fact, miR-24 inhibition increased eNOS 
protein expression in both HMVECs and the mouse peri-infarct 
tissue as well as eNOS activity in CD146+ ECs isolated from the 
peri-infarct myocardium. eNOS protein upregulation induced 
by miR-24 inhibition might contribute to the increased myocar-
dial capillary and arteriole densities together with the improved 
LV perfusion observed at 14 days after MI. Thus far, the pro-
angiogenic effect of miR-24 inhibition has been described to 
be mediated by PAK4 and GATA2.12 The finding that eNOS is 
another target of miR-24 considerably advances our understand-
ing on the mechanisms used by miR-24 to control angiogenesis, 
including in the setting of tissue ischemia. However, as each miR 
can regulate the expression of multiple target genes, we cannot 
exclude that more factors able to modulate vascular biology 
could additionally contribute to the miR-24 anti-angiogenic 
actions.
Fiedler et al. used the systemic delivery of an antagomir to 
inhibit miR-24 in mice with MI.12 By contrast, in our study, in 
vivo miR-24 inhibition was obtained by using an Ad carrying a 
decoy sequence. This tool was prepared consistently with what 
published by Care et al., who previously worked on miR-133.32 
Ad.decoymiR-24 was directly injected in the mouse peri-infarct 
myocardium soon after coronary artery ligation. Our mouse MI 
model is comparable with that used in refs. 12,14,21. Here, using 
Ad-mediated local delivery of miR-24 decoy, we confirmed that 
miR-24 inhibition promotes the formation of new capillaries and 
arterioles in the peri-infarct myocardium. In addition, the incre-
ment in LV perfusion observed after miR-24 inhibition suggests 
the functionality of the newly formed microvessels to supply the 
ischemic region of the myocardium.
Finally, Qian et al. provided evidence of an anti-apoptotic 
effect of miR-24 in cardiomyocytes.14 We confirmed this data 
in vitro as well as in the MI setting. Notwithstanding, in apparent 
contrast with Qian et al.14 and Wang et al.21 who showed therapeu-
tic advantages of overexpressing miR-24 in the mouse infarcted 
heart,14 our study shows an overall positive effect of local miR-
24 inhibition in post-MI LV remodeling and cardiac function. 
Our  in vitro  data confirm the observation previously reported by 
either Fiedler in ECs or Qian in cardiomyocytes and these find-
ings are additionally validated by our  in vivo  data. In addition, 
we newly report that miR-24 inhibition induces fibroblast apop-
tosis, possibly via BIM, which is upregulated in cardiac fibroblast 
after either anti-miR-24 or Ad.decoymiR-24 (versus the respective 
controls). This pro-apoptotic effect on fibroblasts might support 
our finding of reduced infarct size in the heart of  Ad.decoymiR-24 
injected mice.
We believe that, in our experimental model, Ad.decoymiR-24- 
mediated inhibition of miR-24 has an initial predominant effect 
on ECs rather than on cardiomyocytes, thus leading to a potent 
pro-angiogenic response which is possibly accompanied by a 
control of fibroblast expansion at 2 weeks after MI. However, we 
cannot exclude that a prolonged inhibition of miR-24 followed by 
extended apoptosis of cardiomyocytes might have a detrimental 
effect on infarct size and cardiac function.
In conclusion, we have provided strong evidence of the pro-
angiogenic and overall therapeutic effects of miR-24 inhibition in 
the setting of acute MI and revealed for the first time that eNOS is 
a target of miR-24.
MATERIALS AND METHODS
MI protocol in mice. The in vivo experiments were performed in accor-
dance with the Guide for the Care and Use of Laboratory Animals pre-
pared by the Institute of Laboratory Animal Resources and with the prior 
approval of the UK Home Office. MI or sham-operation was induced in 
anaesthetized CD1 male mice, as previously described.25 Briefly, for MI 
induction, mice were anesthetized by intraperitoneal injection of Avertin 
(880 mmol/kg i.p., Sigma, Poole, UK), intubated and artificially venti-
lated using a Minivent mouse ventilator (Harvard Apparatus, Kent, UK). 
Under a surgical microscope, an incision was made at the level of the left 
5th intercostal space and MI was induced by permanent ligation of the 
proximal left anterior descending coronary artery (LAD) by using a 7.0 
Mersilene suture (Ethicon, Somerville, NJ).
Isolation of ECs, cardiomyocytes and fibroblasts from the mouse LV. To 
investigate miR-24 mRNA relative expression in different cardiac cells after 
MI, LVs were harvested at 1, 3 and 14 days after MI or sham-operation. 
Briefly, the peri-infarct area was separated from the remote area and pools 
of 2 samples were rinsed and digested with collagenase II (Worthington, 
Lakewood, NJ) plus DNase I (Sigma) using gentleMACS Dissociator 
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(Miltenyi Biotec, Bisley, UK), following manufacturer’s instructions. Then, 
ECs were immunomagnetic sorted using a CD146 antibody (clone ME-9F1) 
(Miltenyi Biotech).22,38 To verify EC enrichment following CD146+ separa-
tion, single cell suspensions were incubated with FITC-conjugated CD146 
and APC-conjugated CD31 antibodies (or the respective isotype for nega-
tive control). Unstained and single stained controls were performed to define 
positivity. Fluorescence was analyzed in a Canto II flow cytometer using the 
Diva software (BD Biosciences, Oxford, UK). Separation of cardiomyo-
cytes was obtained by sedimentation at room temperature for 10 minutes. 
Cardiomyocyte preparations were validated by staining with a fluorescent 
antibody for α-sarcomeric actin (Sigma). Fibroblasts were isolated form the 
total LV of adult healthy mice (for in vitro experiments) as well as from the 
peri-infarct area and the sham-operated MI. To extract fibroblasts, LVs were 
harvested, minced and digested with liberase (Sigma) for 30 minutes at 37 
°C. Cells were plated for 2 hours and non-adherent cells were then separated 
from adherent fibroblasts. Fibroblast preparations were validated by staining 
with a fluorescent antibody for vimentin (AbCam, Cambridge, UK).
Cells and cell culture. HUVECs and HMVECs (Lonza, Verviers, Belgium) 
were grown in EGM-2 (EBM-2 added with growth factors and other 
supplements, Lonza) with 10% fetal bovine serum and used at P2 to P5. 
HL1 cardiomyocytes (a gift from Prof William Claycomb, Louisiana State 
University Medical Center, New Orleans, LA) were cultured in Claycomb 
medium as originally described.39
Isolation and culture of cardiomyocytes from adult mice. The mouse heart 
was excised and cannulated via the aorta onto a modified Langendorff 
apparatus. All solutions perfusing the heart were gassed with 100% O2 
and heated to 37 °C. Perfusion was performed retrogradely with a myo-
cyte isolation buffer (containing 113 mmol/l NaCl, 4.7 mmol/l KCl, 1.2 
mmol/l MgSO4, 0.6 mmol/l NaH2PO4, 0.6 mmol/l KH2PO4, 10 mmol/l 
HEPES, 10 mmol/l 2, 3 –BDM, 1.6 mmol/l NaHCO3, 20 mmol/l glucose, 
and 30 mmol/l taurine; pH 7.4) followed by an enzyme solution (myo-
cyte isolation buffer containing 1 mg/ml collagenase type 1 (Worthington), 
0.05 mg/ml protease (Sigma) and 0.015 mg/ml DNase I grade 2 (Roche, 
Indianapolis, IN). After 2 minutes of perfusion the enzyme solution was 
supplemented with 50 µmol/l CaCl2 and the heart was perfused for another 
15–20 minutes. The ventricular tissue was then collected and gently disag-
gregated to obtain single cells suspension. The cells were pelleted and resus-
pended in minimum essential medium (with 2.5% fetal bovine serum) for 
1 hour before being infected with either Ad.Null or Ad.decoymiR-24 for 
48 hours (in minimum essential medium without fetal bovine serum). 
Cardiomyocyte preparations were validated by staining with a fluorescent 
antibody for α-sarcomeric actin (Sigma).
Preparation of decoymiR-24 adenoviral vector. For Ad.decoymiR-24 gen-
eration, tandem sequences complementary to miR-24 separated by a 18 bp 
unrelated spacer (decoymiR-24 sequence: 5′-CTGTTCCTGCTGAACT-
GAGCCAagagaacttagagaacttCTGTTCCTGCTGAACTGAGCCA-3′) were 
synthesized as oligonucleotides (Invitrogen) and inserted into XhoI/XbaI 
multicloning site in a TW3′-UTR vector40 (Supplementary Figure S4e). 
After sequencing, the CMV-eGFP decoymiR-24 fragment was subcloned 
into an adenoviral vector, pDC515 (Microbix Biosystems, Miss issauga, 
Ontario, Canada), for adenovirus production. The vector produces a stable 
eGFP transgene under CMV promoter. This design, using multiple copies of 
complementary targets, was intended to optimize the transgene repression 
in the presence of the miRNA.22,40 Replication-deficient adenoviruses were 
generated by site-specific FLP-mediated recombination of the cotransfected 
shuttle and genomic plasmids in 293 cells. Viral stocks were amplified, CsCl 
banded, and titrated as previously described.41 Cells were plated 24 hours 
before infection, incubated with fresh media containing the required mul-
tiplicity of infection (MOI) per cell of virus, left for 6 hours, washed, and 
maintained until harvesting.
Pre-miR-24 and Anti-miR-24 transfection of HUVECs, HMVECs, and 
mouse cardiac fibroblasts. A miR-24 precursor (pre-miR-24, AM17100; 
Ambion-Life Technologies, Paisley, UK) and a miR-24 inhibitor oligonu-
cleotide (anti-miR-24, AM17000; Ambion) and a scrambled oligonucle-
otide (Cy3 dye-labeled anti-miR Negative Control, AM17011; Ambion) 
was transfected into HUVECs, HMVECs or mouse cardiac fibroblasts 
using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA).
Evaluation of apoptosis in cultured cells. HUVECs and HMVECs 
(1.5 × 105/well) were seeded in six-well plates and treated with pre-miR-24, 
anti-miR-24 or negative control (a scramble miR sequence) (all at 50 nmol/
l/l) for 5 hours then kept in Opti-MEM for 48 hours before being trypsin-
ized and plated in a flat-bottomed 96-well plates (4 × 103/well). Caspase-3 
activity was then measured using a luminescent cell death detection kit 
(Caspase-GLO assay; Promega, Southampton, UK). HL1 cells (2 × 105/
well) were seeded in flat-bottomed six-well plates and infected with Ad.
Null or Ad.decoymiR-24 (100 MOI each) for 24 hours, then trypsinized 
and plated in a 96-well plates (5 × 103/well) to perform Caspase-GLO assay 
or Cell Death Detection ELISA assay (Roche) following manufacturer’s 
instructions. Adult mouse cardiomyocytes (2 × 103/well) or cardiac fibro-
blasts (5 × 103/well) were seeded in a 96-well plates and infected with Ad.
Null or Ad.decoymiR-24 (100 MOI each) for 48 hours before performing 
Caspase-GLO assay. Additional cardiac fibroblasts were transfected with 
anti-miR-24 or scramble (control) before undergo Caspase-GLO assay. For 
Caspase-GLO assay, the luminometer reading were taken at 30 minutes 
after adding the Caspase-GLO reagent.
Evaluation of tube-like structures by Matrigel assay. HUVECs and 
HMVECs (1.5 × 104/well) were seeded in six-well plates and treated with 
pre-miR-24, anti-miR-24 or scramble control for 48 hours, then trypsin-
ized and plated in a flat-bottomed 96-well plates (8 × 103/well) coated with 
growth factors-enriched Matrigel (Matrigel Matrix, Basement Membrane, 
BD). Endothelial network formation was quantified at 5 hours in randomly 
captured microscopic fields (magnification 40×) by counting the length 
of cellular network and by measuring the % of area covered by connected 
vascular-like structures.
BrdU incorporation assay. BrdU proliferation assay was performed on 
HUVECs and HMVECs transfected with pre-miR-24, anti-miR-24, or 
scramble control. At 48 hours after transfection, ECs (4 × 103 cells/well) 
were seeded on 96-well plates. The medium was then replaced with a com-
plete medium added with BrdU (10 μmol/l) for 24 hours. BrdU incorpora-
tion was measured by the BrdU ELISA assay kit (Roche).
Bioinformatic prediction of miR-24 target genes. MiRwalk (http://www.
umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html) was searched for 
predicted target genes of miR-24 These analyses were performed allow-
ing miRwalk to search in 9 bioinfomatic platforms, namely DIANAmT, 
miRanda, miRDB, miRWalk, RNAhybrid, PICTAR5, PITA, RNA22, and 
Targetscan.
Luciferase assay. To investigate whether miR-24 directly regulates eNOS 
expression, portions of the 3′-UTR of these potentials target genes were 
inserted downstream of a luciferase open reading frame (pLUC). An 
eNOS 3′-UTR vector was purchased from Origene. For controls, we pre-
pared similar vectors in which five nucleotide mutations were inserted in 
the 3′-UTR sequences (eNOS 3′-UTR: position 119–125) complemen-
tary to the miR-24 “seed” sequences (primers used for mutation are: for-
ward AAGTGCTGCGATTATAGACGatttaatCTGCACCTGG, reverse 
CGTCTATAATCGCAGCACTTTGGGAGGCCGA).
HPLC purified oligonucleotides (Sigma) were used for mutagenesis, 
performed with Pfu enzyme following the in vitro mutagenesis kit 
protocol (Invitrogen). The different luciferase constructs were transfected 
into HEK293 cells together with pre-miR-24 a scrambled oligonucleotide 
sequence (control). Cells were cultured for 48 hours and assayed with the 
Dual-Luciferase Reporter Assay System (Promega). Values are normalized 
using Renilla expression level.
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In vivo nucleic acid therapy. Immediately after LAD ligation, Ad.decoymi-
R24 (108 p.f.u. in 15 µl) or an empty vector (Ad.Null) was injected in the 
peri-infarct myocardium. Sham-operated mice given Ad.Null in the LV 
were used as reference.
Measurement of cardiac dimensions, function and myocardial perfu-
sion. Cardiac dimensions and function were evaluated in anaesthetized 
mice (Avertin) at basal (before the induction of MI) and at 14 days after 
MI by using a High-Resolution Echocardiography System (Visual Sonics, 
Toronto, Ontario, Canada). The following parameters were analyzed: LV 
ejection fraction (EF, %), LV fractional shortening (FS, %), LV chamber 
volume (µl), LV internal diameter (mm). In addition, LV function was 
measured at 14 days after MI with a miniaturized 1.4F transducer Millar 
tip-catheter. Peak systolic LV pressure (mmHg), maximal rate of LV pres-
sure rise (dP/dtmax, mmHg/s) and minimal rate of LVP fall (dP/dtmin, 
mmHg/s) were digitally recorded and analyzed with a dedicated software 
(PowerLab/4SP, ADInstrument).
Myocardial blood flow (ml/minute/g of tissue) was measured 14 
days after MI or sham-operation by using fluorescent microspheres 
(Invitrogen) injected into the LV cavity, as previously described.25 Briefly, 
anesthetized mice (Avertin) were intubated and a polyethylene catheter 
(PE10) was inserted into the right carotid artery and connected to a 
syringe pump for collection of reference blood. Microspheres (0.02 μm 
in diameter) were then injected into the left ventricle cavity (200 μl of 
total volume). Reference blood was collected at a rate of 0.15 ml/minute. 
Mice were killed 2 minute later, the heart was removed and the LV was 
separated, weighed, and minced before being digested in 10 ml of 2 mol/l 
ethanolic KOH (Sigma) at 60 °C for 48 hours. Finally, microspheres were 
collected and fluorescence intensity was determined by a fluorometer. 
Blood flow was additionally measured in the kidneys to confirm the 
homogenous distribution of microspheres into the bloodstream.
Histological analyses. Mice were perfusion/fixed at 14 days after surgery 
and hearts collected and embedded in paraffin. Heart sections including 
the middle part of the infarct, the peri-infarct zone (which contains the bor-
derline area around the MI), and the remote zone (classified as myocardial 
tissue unaffected by the MI) were used. Capillary and arteriole densities 
were measured in transverse sections (5 µm thickness) of the LV peri-
infarct zone. Density of arterioles was evaluated after staining for α-smooth 
muscle actin (α-SMA, for marking vascular smooth muscle cells) and with 
isolectin-B4 (EC marker). Capillary density was evaluated in the same sec-
tions by counting the number of isolectin B4-positive and α-SMA-negative 
microvessels (40× magnification). Apoptosis of ECs and cardiomyocytes 
was determined by transferase-mediated dUTP nick-end labeling (TUNEL) 
assay (40× magnification) (in situ cell death detection kit Fluorescein; 
Roche). TUNEL assay was performed in combination with isolectin-B4 (to 
determine apoptotic ECs), α-sarcomeric actin (to distinguish apoptotic car-
diomyocytes) or vimentin (to recognize apoptotic fibroblasts).
Determination of myocardial infarct size. Infarct size at 2 weeks after MI 
was determined by triphenyltetrazolium chloride (Sigma) staining. Briefly, 
the hearts were collected and sliced transversely to yield five slices. Slices 
were incubated in 1% triphenyltetrazolium chloride for 10 minutes at 37 
°C and fixed in 10% formalin. The area of infarction in both sides was 
determined by an imager analyzer, summed for each hearts and infarct 
size was expressed as a percentage of the LV.
Determination of protein and gene expression in the mouse heart. For 
RT-PCR analyses, cardiac regions (LV, RV, and septum of sham-operated 
mice and LV peri-infarct, LV remote area, RV and septum of MI mice) 
were isolated at 1, and 3 days after surgery. Protein expressional analyses 
were performed in LV peri-infarct zone or LV of sham-operated mice 
at 3 days after surgery. Briefly, mice were anaesthetized (Avertin), the 
heart removed and the required cardiac regions separated and immedi-
ately snap-frozen in liquid nitrogen for subsequent extraction of either 
mRNA or protein. Total RNA was extracted using the miRNeasy mini 
kit (Qiagen, Crawley, UK) and RNA concentration measured with the 
NanoDrop spectrophotometer. Real time quantification to measure 
miR-24 was performed with the TaqMan miRNA reverse transcrip-
tion kit and miRNA Assay (Applied Biosystems, Carlsbad, CA). miR-
24 expression was normalized to the U6 small nucleolar RNA (snRU6) 
(Applied Biosystem). Primers identification numbers for miRs were as 
follows: miR-24: Assay ID 000402; snRU6: Assay ID 001973 (Applied 
Biosystem). Relative miR-24 expression data reported to the control 
group by the 2-∆∆Ct formula. For mRNA analysis, single-strand comple-
mentary DNA was synthetized from 500 ng of total RNA. Quantitative 
reverse transcription PCR (RT-PCR) was used to measure miR-24 tar-
get genes. 18S ribosomal RNA was used for normalization. The primers 
used for mRNA expressional analyses are indicated in Supplementary 
Table S1. Relative target gene mRNA expression data reported to the 
control group by the 2-∆∆Ct formula.
Proteins were extracted from either mouse LV samples using RIPA 
buffer and western blot analyses were performed loading the equivalent 
of 50 µg of total proteins resolved by SDS-PAGE and transferred to 
a nitrocellulose membrane (Amersham Bioscience, Piscataway, NJ). 
Primary antibodies were: total eNOS (Santa Cruz Biotechnology, Santa 
Cruz, CA) and tubulin (loading control; Research Diagnostics, Flanders, 
NJ). Secondary antibody was anti-rabbit horseradish peroxidase conjugate 
(Amersham Bioscience).
Determination of protein and gene expression in cells. Total RNA was 
extracted from HMVECs, HL1 and CD146+ ECs, adult mouse cardiomyo-
cytes and fibroblasts (isolated as described above) using the miRNeasy mini 
kit (Qiagen, Crawley, UK) and RNA concentration was measured with the 
NanoDrop spectrophotometer. Real time quantification to measure miR-
24 was performed with the TaqMan miRNA reverse transcription kit and 
miRNA Assay. miR-24 expression was normalized as described above. For 
mRNA analysis, single-strand complementary DNA was synthetized from 
500 ng of total RNA. Methods for mRNA analyses and quantification are 
described above. Protein extraction and western blot analyses on cultured 
ECs were performed as described above.
eNOS activity assay. eNOS-derived nitric oxide production was evaluated 
in CD146+ ECs isolated from the peri-infarct LV at 3 days after infection 
with Ad.Null or Ad.decoymiR-24. After isolation, cells were loaded with 
10 µmol/l of the rhodamine-based fluorescent chromophore DAR4M-AM 
(Sigma) in Dulbecco’s modified Eagle’s medium (without phenol red) for 
30 minutes at 37 °C. Nitric oxide production was evaluated by using a 
fluorometer.
Statistical analyses. Values are presented as mean ± SEM. Statistical sig-
nificance was evaluated through the use of an unpaired t-test for compari-
sons between two groups. For comparison among more than two groups, 
ANOVA was used, followed by an unpaired t-test. Analyses were per-
formed using the SigmaStat 3.1 software (Sigma). A P value of <0.05 was 
interpreted to denote statistical significance.
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